Peiminine ameliorates bleomycin-induced acute lung injury in rats

Guo,Hai; Ji,Fuzhi; Liu,Baorui; Chen,Xiaofei; He,Jingdong; Gong,Jiening

doi:10.3892/mmr.2013.1312

Peiminine ameliorates bleomycin-induced acute lung injury in rats

Authors:
- Hai Guo
- Fuzhi Ji
- Baorui Liu
- Xiaofei Chen
- Jingdong He
- Jiening Gong
View Affiliations

Affiliations: Cancer Center, Huai'an First People's Hospital, Huai'an 223300, P.R. China, Basic Medical College of Nanjing University of Traditional Chinese Medicine, Nanjing 210046, P.R. China
Published online on: February 7, 2013 https://doi.org/10.3892/mmr.2013.1312
Pages: 1103-1110

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate whether or not peiminine inhibits lung inflammation and pulmonary fibrosis in a rat model of bleomycin-induced lung injury. Rats were randomly divided into 4 groups. In 3 groups, intratracheal bleomycin (5 mg/kg) was used to induce acute lung injury, followed by administration of either carboxymethyl cellulose (control group, n=14), dexamethasone (DXS group, n=14) or peiminine (peiminine group, n=10). In the fourth group (sham-operated, n=12), normal saline was instilled instead of bleomycin, followed by administration of carboxymethyl cellulose. Drugs were administered intragastrically for 28 days. Lung sections were stained with hematoxylin and eosin (H&E) and Masson's trichrome, to grade the degree of alveolitis and pulmonary fibrosis. The lung index was calculated as the ratio of lung to body weight. Serum levels of interleukin-4 (IL-4), tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) were obtained using a radioimmunoassay. Immunocytochemical methods were employed to assess the expression of transforming growth factor-β (TGF-β), connective tissue growth factor (CTGF), NF-κB, extracellular signal-related kinase (ERK1/2), Fas and FasL in lung tissue. Peiminine and DXS significantly reduced alveolar inflammation and pulmonary interstitial inflammation in rats with bleomycin-induced lung injury. These protective effects were associated with significant (P<0.05) decreases in the levels of IFN-γ in serum and of TGF-β, CTGF, ERK1/2, NF-κB and FasL in lung tissue. No effects were observed on serum TNF-α or IL-4. In conclusion, peiminine inhibits lung inflammation and pulmonary fibrosis in a rat model of bleomycin-induced lung injury, by reducing circulating IFN-γ levels and inhibiting signal transduction pathways involving TGF-β, CTGF, ERK1/2, NF-κB and FasL.

View Figures

View References

1	Limper AH: Chemotherapy-induced lung disease. Clin Chest Med. 25:53–64. 2004. View Article : Google Scholar
2	Graves PR, Siddiqui F, Anscher MS and Movsas B: Radiation pulmonary toxicity: from mechanisms to management. Semin Radiat Oncol. 20:201–207. 2010. View Article : Google Scholar : PubMed/NCBI
3	Bhatia M, Zemans RL and Jeyaseelan S: Role of chemokines in the pathogenesis of acute lung injury. Am J Respir Cell Mol Biol. 46:566–572. 2012. View Article : Google Scholar : PubMed/NCBI
4	Martin TR and Matute-Bello G: Experimental models and emerging hypotheses for acute lung injury. Crit Care Clin. 27:735–752. 2011. View Article : Google Scholar : PubMed/NCBI
5	Mukhopadhyay S, Hoidal JR and Mukherjee TK: Role of TNFalpha in pulmonary pathophysiology. Respir Res. 7:1252006. View Article : Google Scholar : PubMed/NCBI
6	Anscher MS: Targeting the TGF-beta1 pathway to prevent normal tissue injury after cancer therapy. Oncologist. 15:350–359. 2010. View Article : Google Scholar : PubMed/NCBI
7	Wilson MS, Madala SK, Ramalingam TR, et al: Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med. 207:535–552. 2010. View Article : Google Scholar : PubMed/NCBI
8	Blom IE, Goldschmeding R and Leask A: Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? Matrix Biol. 21:473–482. 2002. View Article : Google Scholar : PubMed/NCBI
9	Madala SK, Schmidt S, Davidson C, Ikegami M, Wert S and Hardie WD: MEK-ERK pathway modulation ameliorates pulmonary fibrosis associated with epidermal growth factor receptor activation. Am J Respir Cell Mol Biol. 46:380–388. 2012. View Article : Google Scholar : PubMed/NCBI
10	Antoniou KM, Margaritopoulos GA, Soufla G, et al: Expression analysis of Akt and MAPK signaling pathways in lung tissue of patients with idiopathic pulmonary fibrosis (IPF). J Recept Signal Transduct Res. 30:262–269. 2010. View Article : Google Scholar : PubMed/NCBI
11	Jia X, Liu B, Shi X, Ye M, Zhang F and Liu H: Roles of the ERK, JNK/AP-1/cyclin D1-CDK4 pathway in silica-induced cell cycle changes in human embryo lung fibroblast cells. Cell Biol Int. 35:697–704. 2011. View Article : Google Scholar : PubMed/NCBI
12	Morris GF: An alternative to lung inflammation and fibrosis. Am J Pathol. 176:2595–2598. 2010. View Article : Google Scholar : PubMed/NCBI
13	Vallabhapurapu S and Karin M: Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol. 27:693–733. 2009. View Article : Google Scholar : PubMed/NCBI
14	Johnson ER and Matthay MA: Acute lung injury: epidemiology, pathogenesis, and treatment. J Aerosol Med Pulm Drug Deliv. 23:243–252. 2010. View Article : Google Scholar : PubMed/NCBI
15	Lamontagne F, Briel M, Guyatt GH, Cook DJ, Bhatnagar N and Meade M: Corticosteroid therapy for acute lung injury, acute respiratory distress syndrome, and severe pneumonia: a meta-analysis of randomized controlled trials. J Crit Care. 25:420–435. 2010. View Article : Google Scholar
16	Raghu G, Collard HR, Egan JJ, et al: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 183:788–824. 2011. View Article : Google Scholar : PubMed/NCBI
17	Wang D, Zhu J, Wang S, et al: Antitussive, expectorant and anti-inflammatory alkaloids from Bulbus Fritillariae Cirrhosae. Fitoterapia. 82:1290–1294. 2011. View Article : Google Scholar : PubMed/NCBI
18	Wang D, Wang S, Chen X, et al: Antitussive, expectorant and anti-inflammatory activities of four alkaloids isolated from Bulbus of Fritillaria wabuensis. J Ethnopharmacol. 139:189–193. 2012. View Article : Google Scholar : PubMed/NCBI
19	Taooka Y, Maeda A, Hiyama K, Ishioka S and Yamakido M: Effects of neutrophil elastase inhibitor on bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med. 156:260–265. 1997. View Article : Google Scholar : PubMed/NCBI
20	Aono Y, Nishioka Y, Inayama M, et al: Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med. 171:1279–1285. 2005. View Article : Google Scholar : PubMed/NCBI
21	Szapiel SV, Elson NA, Fulmer JD, Hunninghake GW and Crystal RG: Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. Am Rev Respir Dis. 120:893–899. 1979.PubMed/NCBI
22	El-Demerdash E: Anti-inflammatory and antifibrotic effects of methyl palmitate. Toxicol Appl Pharmacol. 254:238–244. 2011. View Article : Google Scholar : PubMed/NCBI
23	Kim JW, Rhee CK, Kim TJ, et al: Effect of pravastatin on bleomycin-induced acute lung injury and pulmonary fibrosis. Clin Exp Pharmacol Physiol. 37:1055–1063. 2010. View Article : Google Scholar : PubMed/NCBI
24	Hardie WD, Glasser SW and Hagood JS: Emerging concepts in the pathogenesis of lung fibrosis. Am J Pathol. 175:3–16. 2009. View Article : Google Scholar : PubMed/NCBI
25	Zhao L, Wang X, Chang Q, et al: Neferine, a bisbenzylisoquinline alkaloid attenuates bleomycin-induced pulmonary fibrosis. Eur J Pharmacol. 627:304–312. 2010. View Article : Google Scholar : PubMed/NCBI
26	Liu Y, Wu H, Nie YC, Chen JL, Su WW and Li PB: Naringin attenuates acute lung injury in LPS-treated mice by inhibiting NF-κB pathway. Int Immunopharmacol. 11:1606–1612. 2011.PubMed/NCBI
27	Lee HB, Kim EK, Park SJ, Bang SG, Kim TG and Chung DW: Isolation and anti-inflammatory effect of astragalin synthesized by enzymatic hydrolysis of tea seed extract. J Sci Food Agric. 91:2315–2321. 2011. View Article : Google Scholar : PubMed/NCBI
28	Fu PK, Wu CL, Tsai TH and Hsieh CL: Anti-inflammatory and anticoagulative effects of paeonol on LPS-induced acute lung injury in rats. Evid Based Complement Alternat Med. 2012:8375132012.PubMed/NCBI
29	Lee JP, Li YC, Chen HY, et al: Protective effects of luteolin against lipopolysaccharide-induced acute lung injury involves inhibition of MEK/ERK and PI3K/Akt pathways in neutrophils. Acta Pharmacol Sin. 31:831–838. 2010. View Article : Google Scholar : PubMed/NCBI
30	Soromou LW, Chen N, Jiang L, et al: Astragalin attenuates lipopolysaccharide-induced inflammatory responses by down-regulating NF-κB signaling pathway. Biochem Biophys Res Commun. 419:256–261. 2012.PubMed/NCBI
31	Levings MK and Schrader JW: IL-4 inhibits the production of TNF-alpha and IL-12 by STAT6-dependent and -independent mechanisms. J Immunol. 162:5224–5229. 1999.PubMed/NCBI
32	Carey WA, Taylor GD, Dean WB and Bristow JD: Tenascin-C deficiency attenuates TGF-β-mediated fibrosis following murine lung injury. Am J Physiol Lung Cell Mol Physiol. 299:L785–L793. 2010.
33	Acloque H, Adams MS, Fishwick K, Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest. 119:1438–1449. 2009. View Article : Google Scholar : PubMed/NCBI
34	Xu J, Lamouille S and Derynck R: TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 19:156–172. 2009. View Article : Google Scholar : PubMed/NCBI
35	Ramos C, Becerril C, Montano M, et al: FGF-1 reverts epithelial-mesenchymal transition induced by TGF-{beta}1 through MAPK/ERK kinase pathway. Am J Physiol Lung Cell Mol Physiol. 299:L222–L231. 2010.PubMed/NCBI
36	Kono M, Nakamura Y, Suda T, et al: Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF). Clin Chim Acta. 412:2211–2215. 2011. View Article : Google Scholar : PubMed/NCBI
37	Leask A, Parapuram SK, Shi-Wen X and Abraham DJ: Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease? J Cell Commun Signal. 3:89–94. 2009. View Article : Google Scholar : PubMed/NCBI
38	Dosreis GA, Borges VM and Zin WA: The central role of Fas-ligand cell signaling in inflammatory lung diseases. J Cell Mol Med. 8:285–293. 2004. View Article : Google Scholar : PubMed/NCBI